Breast cancer Posts on Medivizor
Navigation Menu

Breast cancer Posts on Medivizor

Reducing chemotherapy-induced toxicities in patients with breast cancer using anti-diabetes medication metformin.

Reducing chemotherapy-induced toxicities in patients with breast cancer using anti-diabetes medication metformin.

Posted by on Sep 17, 2023 in Breast cancer | 0 comments

In a nutshell This study investigated the beneficial effects of co-administering anti-diabetes medication metformin (Glucophage) and doxorubicin (Adriamycin)-cyclophosphamide (Cytoxan) with paclitaxel (Taxol) (AC-T) chemotherapy in non-diabetic patients with breast cancer (BC). The data showed that metformin reduced the occurrence and severity of...

Read More

Investigating the effectiveness of compression bandage applied with different pressures on the skin and subcutaneous tissue thickness in patients with breast cancer-related lymphedema

Investigating the effectiveness of compression bandage applied with different pressures on the skin and subcutaneous tissue thickness in patients with breast cancer-related lymphedema

Posted by on Jul 30, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the effectiveness of compression bandages applied with different pressures on the skin and subcutaneous tissue in patients with breast cancer-related lymphedema (BCRL). The study concluded that high-pressure compression bandage was more effective in reducing skin and subcutaneous tissue thickness and inflammation in...

Read More

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Posted by on Jul 2, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the follow-up results of abemaciclib (Verzenio) plus endocrine (hormonal) therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive, and high-risk early breast cancer (BC). The data found that with a 4-year follow-up, adjuvant abemaciclib continued to show improvement in reducing the...

Read More

Comparing the long-term effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer

Comparing the long-term effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer

Posted by on Jun 11, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of trastuzumab deruxtecan (TD; Enhertu) with trastuzumab emtansine (TE; Kadcyla) in patients with HER2-positive (HER2+) metastatic breast cancer (BC). The study found that TD was more effective and well-tolerated compared to TE in these patients. Some background HER2+ BC...

Read More

Comparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer

Comparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer

Posted by on May 28, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the long-term effectiveness of accelerated partial breast irradiation (ABPI) using multicatheter brachytherapy (BT) with whole-breast irradiation (WBI) in patients with early breast cancer (BC). The study found that ABPI using multicatheter BT was similarly effective with fewer serious side effects compared to...

Read More

Evaluating the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple negative breast cancer.

Evaluating the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple negative breast cancer.

Posted by on May 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of taxanes combined with chemotherapy in patients with advanced triple-negative breast cancer (TNBC). This study concluded that the combination of taxanes and chemotherapy is effective with manageable side effects in these patients. Some background TNBC is a subtype of BC that tests...

Read More

Evaluating the effectiveness of physical exercise programs in breast cancer survivors on health-related quality of life, physical fitness, and body composition

Evaluating the effectiveness of physical exercise programs in breast cancer survivors on health-related quality of life, physical fitness, and body composition

Posted by on Apr 30, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the effectiveness of physical exercise (PE) programs in breast cancer (BC) survivors on health-related quality of life (HRQoL), physical fitness, and body composition. The study concluded that PE programs do have a positive impact on BC survivors’ HRQoL, physical fitness, and body composition. Some background...

Read More

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Posted by on Apr 30, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...

Read More

Evaluating the effectiveness and safety of a tumor bed boost after whole breast irradiation following breast-conserving surgery in patients with non-low-risk ductal carcinoma in situ.

Evaluating the effectiveness and safety of a tumor bed boost after whole breast irradiation following breast-conserving surgery in patients with non-low-risk ductal carcinoma in situ.

Posted by on Apr 23, 2023 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of a tumor bed (where the tumor was present) boost after whole breast irradiation (WBI) following breast-conserving surgery (BCS) in patients with non-low-risk ductal carcinoma in situ (DCIS). The data showed that a tumor bed boost after WBI following BCS reduced local recurrence (return...

Read More

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2– metastatic breast cancer.

Posted by on Apr 23, 2023 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC). The data showed that SG significantly improved survival without cancer progression compared to chemotherapy in these...

Read More

Evaluating the effects of aquatic physical therapy on fatigue symptoms and quality of life in patients with breast cancer.

Evaluating the effects of aquatic physical therapy on fatigue symptoms and quality of life in patients with breast cancer.

Posted by on Apr 15, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effects of aquatic physical therapy on improvement in fatigue symptoms and quality of life (QoL) in patients with breast cancer (BC). The data showed that aquatic physical therapy reduced fatigue symptoms and improved the QoL in women with BC. Some background Breast cancer (BC) is one of the most common...

Read More

Evaluating the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer.

Evaluating the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer.

Posted by on Mar 24, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer. The data showed that most patients with breast and gynecological cancer developed antibodies after the second dose of the vaccine. However, the authors suggested that for non-responders or weak...

Read More